Chaetomorpha linum polysaccharides alleviate NAFLD in mice by enhancing the PPARα/CPT-1/MCAD signaling

Lipids Health Dis. 2022 Dec 19;21(1):140. doi: 10.1186/s12944-022-01730-x.

Abstract

Background: Green algae contain many polysaccharides. However, there is no information on whether Chaetomorpha linum polysaccharides (CLP) can modulate lipid and glucose metabolism.

Material and methods: CLP were extracted from chlorella and their components were characterized. Male C57BL/6 mice were randomized and provided with control chow as the control, or high fat diet (HFD) to induce nonalcoholic fatty liver disease (NAFLD). NAFLD mice were treated orally with water as the HFD group or with 50 or 150 mg/kg CLP daily for 10 weeks. The impact of CLP treatment on lipid and glucose metabolism and the PPARα signaling was examined by histology, Western blotting and biochemistry.

Results: CLP mainly contained arabinogalactan sulfate. Compared with the control, HFD feeding increased body weights, lipid droplet liver deposition and induced hyperlipidemia, liver functional impairment and glucose intolerance in mice. Treatment with CLP, particularly with a higher dose of CLP, limited the HFD-increased body weights and liver lipid droplet deposition, mitigated the HFD-induced hyperlipidemia and improved liver function and glucose tolerance in mice. Mechanistically, feeding with HFD dramatically decreased the expression of liver PPARα, CPT-1, and MCAD, but treatment with CLP enhanced their expression in a trend of dose-dependent in mice.

Conclusions: These findings indicated that CLP treatment alleviated the gain in body weights, NAFLD, and glucose intolerance in mice after HFD feeding by enhancing the PPARα/CPT-1/MCAD signaling.

Keywords: Arabinogalactan; Chaetomorpha linum polysaccharide; Glucose tolerance; Mice; Nonalcoholic fatty liver disease.

MeSH terms

  • Animals
  • Carnitine O-Palmitoyltransferase / metabolism
  • Chlorella*
  • Diet, High-Fat / adverse effects
  • Flax*
  • Glucose / metabolism
  • Glucose Intolerance* / pathology
  • Hyperlipidemias* / pathology
  • Lipid Metabolism
  • Lipids / therapeutic use
  • Liver / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Non-alcoholic Fatty Liver Disease* / drug therapy
  • Non-alcoholic Fatty Liver Disease* / genetics
  • Non-alcoholic Fatty Liver Disease* / metabolism
  • PPAR alpha / genetics
  • PPAR alpha / metabolism
  • Polysaccharides / pharmacology
  • Polysaccharides / therapeutic use
  • Weight Gain

Substances

  • PPAR alpha
  • Carnitine O-Palmitoyltransferase
  • Glucose
  • Polysaccharides
  • Lipids